Clinical trials: Healthy Control Group
Healthy Population
Evaluation of the Tolerance of Three Masks Under Dermatological Control.
This is a monocentric, open and randomized study. The purpose is to evaluate the cutaneous tolerance of three medical masks (class I medical device) after 3 consecutive days of use on a population with normal or sensitive skin.
- Trial name
- NCT05193799
- Testing
- Investigational devices must be used 8 hours per day
- Where
- France
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Groupe Kolmi Hopen
Contraception
EU/LA Pearl Index Study - Transdermal Contraceptive Patch
The aim of the present study is to prove efficacy and safety of a new contraceptive patch.
- Trial name
- NCT00914693
- Testing
- Ethinylestradiol/Gestodene (BAY86-5016)
- Where
- 66 sites in Argentina, Australia and 6 more
- Volunteers
- 1,694 people
- Sponsor
- Bayer
Healthy
A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men
The main objectives of this trial are to investigate safety, tolerability. pharmacokinetics (PK), and pharmacodynamics of BI 1815368 in healthy Japanese male subjects following administration of single rising doses or multiple…
- Trial name
- NCT06494774
- Testing
- BI 1815368
- Where
- Japan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Androgenetic Alopecia
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following…
- Trial name
- NCT04984707
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Healthy
Safety and Tolerability of Lu AG06474 in Healthy Young Men
The purpose of this study is to investigate the safety and tolerability of Lu AG06474 and what the body does to Lu AG06474 after swallowing single doses of the drug.
- Trial name
- NCT05003687
- Testing
- Lu AG06474
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Renal Impairment
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function
The primary objective is to evaluate pharmacokinetics of Fluzoparib and its main metabolite in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal…
- Trial name
- NCT05032235
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cranial Waveform in Normal Patients as a Result of Cardiac Cycle, Healthy
500 "Normal" Adult Subjects Who Have Experienced no Known Brain Injury Will Participate in Collecting Data That Will Assist With the Optimization of the Diagnostic Capabilities of the Harmony in Detecting Neurologic Abnormalities.
The REFRESH study is designed to collect data related to a signal in the brain that MindRhythm has named the Headpulse. The Headpulse occurs as a natural movement of the brain in conjunction with the beating of the heart.
- Trial name
- REFRESH (NCT05203393)
- Testing
- Harmony Headset
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- MindRhythm, Inc.
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers
This study is designed to evaluate the safety and plasma concentrations of PF-06649751 in healthy volunteers following one or two times daily oral dosing of PF-06649751 for 14 days (Cohorts 1 - 4), 21 days (Cohort 5), or 28 days…
- Trial name
- NCT02066909
- Testing
- 0.15 mg PF-06649751, 0.5 mg PF-06649751, 1.5 mg PF-06649751
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Pfizer
Parkinson's Disease
Single Ascending Dose Study Investigating the Safety, Tolerability, and PK of XC130-A10H in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. Up to 5 cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
- Trial name
- NCT04043338
- Testing
- XC130-A10H
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Xoc Pharmaceuticals
Healthy
Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers
The main purpose of this study is to assess the safety and tolerability of AZD5847 after receiving oral doses on a single day (Part A) or after receiving a single oral dose in two periods (Part B).
- Trial name
- NCT01037725
- Testing
- AZD5847
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)
This study involves the use of an investigational drug called NGP 555. In each group of healthy subjects, 2 people will receive placebo and 6 people will receive NGP 555.
- Trial name
- NCT02537938
- Testing
- NGP 555
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- NeuroGenetic Pharmaceuticals Inc
Stroke, Stroke, Acute
Phase 1 Study to Assess AER-271
The objective of this Phase 1 trial is to assess the safety, tolerability and pharmacokinetics of AER-271 in health subjects.
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic
- Trial name
- NCT03804476
- Testing
- AER-271
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Aeromics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to assess the safety and tolerability (maximum tolerated dose) after single and multiple doses of NNC 90-1170 (liraglutide) in healthy volunteers and in subjects with…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01507285
- Testing
- liraglutide
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diphtheria, Hepatitis B
Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.
The purpose of this study is to compare the reactogenicity \& safety of Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care, Tritanrix™-HepB/Hiberix™.
- Conditions
- Diphtheria, Hepatitis B, Whole Cell Pertussis, Haemophilus Influenzae Type b
- Trial name
- NCT00317135
- Testing
- Tritanrix-HepB/Meningitec conjugate vaccine, Tritanrix/Hiberix vaccine
- Where
- Philippines
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers
Evaluation of safety, tolerability and pharmacokinetics of single rising intravenous doses of BEA 2180 BR; additional exploration of metabolism following inhalation
- Trial name
- NCT02254720
- Testing
- BEA 2180 BR solution for infusion, BEA 2180 BR solution for inhalation, Respimat®
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
COVID-19
A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
A phase III, randomized, observer-blind, active-controlled, parallel-group, multi-center study to evaluate immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 in healthy adults aged 18 years and older
- Trial name
- NCT05603052
- Testing
- EuCorVac-19, ChAdOx1 nCoV-19
- Where
- Democratic Republic of the Congo
- Volunteers
- 2,852 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Pneumococcal Infection
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
phase-1 study pneumococcal conjugate vaccine study in healthy adults
- Trial name
- NCT03549208
- Testing
- LBVE01, LBVE02, Prevnar13
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Chem
Healthy
First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects
This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a Janus kinase1 (JAK1) inhibitor, in humans.
- Trial name
- NCT01835197
- Testing
- PF-04965842
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)
This study aims to investigate the bioequivalence of new formulation of bevacizumab called CBT124 and safety when compared to two already marketed formulations, one approved in US and other in EU of Avastin(Registered Trademark).
- Trial name
- CBT124NHV001 (NCT02747823)
- Testing
- CBT124, EU Sourced Avastin®, US Sourced Avastin®
- Where
- New Zealand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Cipla BioTec Pvt. Ltd.
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects
The objective of this study was to obtain safety and tolerability data and first pharmacokinetic and pharmacodynamic data of escalating doses of ESR 1150 CL.
- Trial name
- NCT02209688
- Testing
- ESR 1150 CL
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim